Research ArticleBasic Science Investigation
Characterization of [18F]Fluoroetanidazole, a New Radiopharmaceutical for Detecting Tumor Hypoxia
Janet S. Rasey, Philip D. Hofstrand, Lay K. Chin and Timothy J. Tewson
Journal of Nuclear Medicine June 1999, 40 (6) 1072-1079;
Janet S. Rasey
Philip D. Hofstrand
Lay K. Chin
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Characterization of [18F]Fluoroetanidazole, a New Radiopharmaceutical for Detecting Tumor Hypoxia
Janet S. Rasey, Philip D. Hofstrand, Lay K. Chin, Timothy J. Tewson
Journal of Nuclear Medicine Jun 1999, 40 (6) 1072-1079;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Imaging hypoxia in gliomas
- Molecular Imaging of Hypoxia
- Applications of Nitroimidazole In Vivo Hypoxia Imaging in Ischemic Stroke
- Reduced Expression of Hypoxia-Inducible Factor-1{alpha} in Perinecrotic Regions of Solid Tumors
- Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside
- Assessment of Hypoxia and Perfusion in Human Brain Tumors Using PET with 18F-Fluoromisonidazole and 15O-H2O
- Hypoxia and Glucose Metabolism in Malignant Tumors: Evaluation by [18F]Fluoromisonidazole and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging
- Imaging of Ischemic but Viable Myocardium Using a New 18F-Labeled 2-Nitroimidazole Analog, 18F-FRP170
- Pharmacokinetics of [18F]FETNIM: A Potential Hypoxia Marker for PET